News|Articles|November 16, 2026

Belzutifan Plus Lenvatinib Earns Positive CHMP Opinion in Advanced ccRCC

Fact checked by: Roman Fabbricatore

The CHMP recommended belzutifan plus lenvatinib for advanced clear cell RCC after anti–PD-(L)1 therapy, based on phase 3 LITESPARK-011 data.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of belzutifan (Welireg) plus lenvatinib (Lenvima) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following treatment with a PD-1 or PD-L1 inhibitor, according to a news release from the developer, Merck.1

The recommendation is based on data from the phase 3 LITESPARK-011 trial (NCT04586231). If approved, the regimen would be the first combination of a HIF-2α inhibitor and a multitargeted VEGFR tyrosine kinase inhibitor available in the EU, according to the company

“Patients with advanced renal cell carcinoma in the [EU] have limited treatment options,” said Christina Derleth, MD, vice president of global oncology clinical development at Merck Research Laboratories, in the news release.1 “This positive opinion is a meaningful step toward potentially bringing this first-of-its-kind regimen to patientsin need … and underscores the important role of [belzutifan] plus lenvatinib as a new option in the treatment of renal cell carcinoma.”

What data support the CHMP opinion for belzutifan plus lenvatinib?

In LITESPARK-011, belzutifan plus lenvatinib significantly improved progression-free survival (PFS) vs cabozantinib (Cabometyx), reducing the risk of progression or death by 26% (HR, 0.74; 95% CI, 0.61-0.89; P = 0.001). The median PFS was 14.6 months (95% CI, 11.1-16.6) vs 10.6 months (95% CI, 9.2-11.1), respectively.2 Overall survival (OS) did not reach statistical significance at the final analysis (HR, 0.85; 95% CI, 0.70-1.03), with a median OS of 33.7 months (95% CI, 29.0-46.9) vs 28.6 months (95% CI, 24.1-31.4).

According to final results presented at the 2026 European Society for Medical Oncology (ESMO) Congress, the objective response rate (ORR) was 53.1% (95% CI, 47.9%-58.3%) with the combination vs 40.2% (95% CI, 35.2%-45.3%) with cabozantinib, and the median duration of response (DOR) was 22.0 months (range, 2.0 to 52.2+) vs 11.9 months (range, 1.8+ to 44.1+), respectively.3

What is the LITESPARK-011 trial design?

The randomized, open-label, phase 3 trial enrolled 747 patients with locally advanced or metastatic ccRCC whose disease progressed on or after a PD-1 or PD-L1 inhibitor, or within 6 months of completing adjuvant PD-1 inhibitor therapy. Patients received belzutifan 120 mg once daily plus lenvatinib 20 mg once daily or cabozantinib 60 mg once daily.

The dual primary end points were PFS per RECIST v1.1 by blinded independent central review and OS. Secondary end points included objective response rate, duration of response, and safety.

What safety signals were observed with belzutifan plus lenvatinib?

Among patients who received the combination, anemia (decreased hemoglobin) occurred in 87%, with 20% experiencing grade 3 events or requiring transfusion; the median time to onset was 56 days. Hypoxia occurred in 16% of patients, including grade 3 or 4 hypoxia in 12%, and grade 3 or higher cardiac dysfunction occurred in 6%.

Serious adverse reactions occurred in 54% of patients, most commonly hypoxia (6%) and pneumonia (5%), and fatal adverse reactions occurred in 5%. Adverse reactions led to permanent discontinuation of belzutifan in 17% of patients, dose interruptions in 69%, and dose reductions in 35%.

What is the US regulatory status of the combination?

The FDA approved belzutifan plus lenvatinib for adults with advanced ccRCC following a PD-1 or PD-L1 inhibitor on September 24, 2026, based on the LITESPARK-011 data.3

References

  1. Merck receives positive EU CHMP opinion for WELIREG (belzutifan) in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following treatment with a PD-1 or PD-L1 inhibitor. News release. Merck. November 13, 2026. Accessed November 16, 2026. https://tinyurl.com/2998tw69
  2. Heng DYC, McDermott R, Park SH, et al. Final analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy. Presented at: 2026 European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. Abstract 3587O
  3. FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component. News release. FDA. September 24, 2026. Accessed November 16, 2026. https://tinyurl.com/ynx76c3x

Related to this article